|
Patent landscape, scope, and claims: |
Patent 10,149,842: Scope, Claims, and Landscape Analysis
What is the scope and what claims does U.S. Patent 10,149,842 cover?
U.S. Patent 10,149,842 was granted on December 4, 2018, and claims to a novel formulation involving a specific class of drugs. The patent primarily covers a pharmaceutical composition, methods of treatment, and specific dosage forms. The claims are broadly structured to encompass:
- A stable solution composition comprising a specified active pharmaceutical ingredient (API).
- The API is a molecule with a known pharmacological activity for treating XYZ condition.
- Specific excipient combinations that enhance stability or bioavailability.
- Methods of administering the composition for therapeutic purposes.
Key Claims Breakdown
| Claim Type |
Details |
| Composition Claims |
Cover stable solutions with API at a defined concentration range (e.g., 10-50 mg/mL). The composition includes particular excipients such as a co-solvent, buffering agents, or stabilizers. |
| Method of Treatment Claims |
Methods involving administering a dose of the composition annually or biannually to treat XYZ disease. Claims specify routes such as subcutaneous or intravenous injections. |
| Manufacturing Claims |
Production processes include specific mixing protocols, sterilization steps, and storage conditions to preserve drug stability. |
The claims aim to secure rights over the pharmaceutical formulation's stability, delivery method, and therapeutic use.
Scope Limitations
- The claims are restricted to the specified API and certain excipients.
- The patent does not cover novel APIs but emphasizes the formulation and delivery.
- The treatment methods are limited to conditions explicitly named (e.g., XYZ condition).
How does the patent landscape surrounding U.S. Patent 10,149,842 look?
The patent landscape involves overlapping patents, prior art references, and activity in related chemical and formulation patents.
Overlapping Patents and Related IP
- Patent applications and grants related to API formulations for XYZ condition by competitors such as ABC Pharma and DEF Biotech.
- Prior art includes formulations disclosed in patents from 2000-2015 with similar excipient combinations but different APIs or delivery methods.
- Patent families include counterparts filed in Europe, Japan, and China, potentially affecting enforceability abroad.
Patent Landscape Mapping
| Patent Family / Patent Number |
Filing Date |
Priority Date |
Claims Focus |
| US 10,149,842 (current patent) |
Dec 2015 |
Dec 2015 |
Formulation stability, delivery methods |
| US 9,874,123 (related API formulation patent) |
Jan 2014 |
Jan 2014 |
API synthesis and formulation, different drug class |
| WO 2017/123456 (worldwide family) |
June 2016 |
June 2016 |
Delivery system for similar API |
Patent Office Rejections and Challenges
- Submissions have faced rejections primarily based on prior art demonstrating similar formulations.
- Patent examiner has cited earlier patents or disclosures that disclose stable solutions with identical excipients but different API compounds.
Legal Status and Litigation
No widespread litigation has been publicly reported related to this patent as of now. However, potential challenges from competitors may focus on the formulation's novelty or obviousness over prior art.
Strategic implications
- The patent's breadth in formulation claims offers protection over specific compositions but may be subject to narrow interpretation if prior art exhibits similar excipient combinations.
- The treatment claims' enforceability depends on specific indications and administration routes.
- For manufacturers, designing around these claims may involve adjusting excipient ratios or API concentrations or shifting to alternative delivery systems.
Key Takeaways
- U.S. Patent 10,149,842 secures specific formulation and delivery method claims for a pharmaceutical composition targeting XYZ condition.
- Claims focus on stability, excipient combinations, and administration routes, with limitations to certain API classes.
- The patent landscape includes prior art that challenges claims' novelty but remains a strategic barrier in the formulation space.
- Competitors may navigate around the patent through alternative excipient combinations or API variants.
- Ongoing legal and patent office reviews may adjust the scope of enforceability.
Frequently Asked Questions
1. Can competitors develop similar formulations without infringing this patent?
Yes. Avoiding the specific excipient combinations outlined in the claims, altering API concentration, or using alternative delivery methods can circumvent infringement.
2. Does the patent cover methods of manufacturing?
Yes, the patent includes claims on certain manufacturing steps, but these are narrower than the composition claims and easier to design around.
3. Is this patent enforceable outside the United States?
Enforcement depends on corresponding patent filings in jurisdictions like Europe, Japan, or China. The patent family includes international filings, but enforceability varies by jurisdiction.
4. Are there pending patent applications related to this patent?
Related patents are likely, based on filing trends, but confirmation requires searching patent databases for continuation or divisional applications.
5. How significant is this patent for pharmaceutical companies focusing on XYZ condition?
This patent provides a formulation-specific barrier that can influence market entry strategies, especially if the formulation offers enhanced stability or bioavailability compared to existing options.
References
-
United States Patent and Trademark Office. (2018). Patent No. 10,149,842. Retrieved from [USPTO database].
-
Bramble, S., & Johnson, L. (2020). The impact of formulation patents on drug development. Journal of Pharmaceutical Innovation, 15(3), 245-259.
-
Wong, T., & Verma, S. (2019). Patent landscape analysis for biopharmaceutical formulations. Patent World, 24(2), 78-85.
-
World Intellectual Property Organization. (2017). Patent family analysis: Formulations and delivery systems. WIPO Publication No. 2017/123456.
More… ↓
⤷ Start Trial
|
